NAS
ELVN icon

Nykredit A/S’s Enliven Therapeutics ELVN Stock Holding History

Nykredit A/S’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Buy
+259
New +$11K ﹤0.01% 1833

Other funds holding ELVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nykredit A/S's ELVN Position: Q2 2026 in Review

Nykredit A/S opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 259 shares worth $13.1K. The stake represents ﹤0.01% of the portfolio and ranks #1833 among its holdings.

113 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Nykredit A/S held 259 shares of Enliven Therapeutics worth $13.1K as of Q2 2026.
  • Enliven Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1833 holding.
  • 113 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.